Replies to post #10205 on Organovo Holdings, Inc. (ONVO)

[RandolRocketman]

Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
BY GlobeNewswire
— 8:05 AM ET 10/15/2018

The Company’s poster(s) and oral presentation are as follows:

Title: The Performance Characteristics of Isolated Human Liver Cells Correlate
with Donor Attributes in a Cohort of Tissues from Non-Diseased and NAFLD Donors
Date: Saturday, November 10, 2018, 2:00 pm PT – Moscone Center

North/South
Building, Hall C
Publication: 1305

Title: Long-Term Performance of Implanted Bioprinted Human Liver Tissue in a
Mouse Model of Tyrosinemia I (Oral Presentation)

Date: Sunday, November 11, 2018, 11:30 am PT – Moscone Center North/South Building, Room 214/216
Publication: 0083

About Organovo Holdings, Inc. ( ONVO) is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. The Company is pursuing multiple IND-track programs to develop its NovoTissues® to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Organovo’s first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA, and the Company expects to file its first IND in 2020. In order to support its plan to initiate multiple IND-track programs, the Company is providing access to its ExVive™ in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovo’s wholly-owned subsidiary, Samsara Sciences, provides the Company and its clients with high quality human liver and kidney cells for research applications. Organovo ( ONVO) is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.

[RandolRocketman]

Organovo should have enough business going in the samples/ toxicology market to sustain the company for the time needed to get through clinical trials. It's a good company with really good management and staff, so far as I've seen. And even more likely than them going broke would be a tie-up with a big deep pocket entity for funding the trials. Just kidney tissue alone for diabetic patients that are receiving dialysis treatment is a huge market. Then there is liver tissue for Hepatitis type patients, (and heavy drinkers!) Skin grafts for burns victims is another huge market. Don't forget the 700lb gorilla for this technology is the military. In my opinion, the silence on that subject is deafening. The list goes on and on. Just so much upside potential IMHO.
Although I agree with your assessment of a business model of ongoing therapy having more profit than a cure, I don't share your cynicism regarding the way things work in the medical field regarding disruptive therapies. EVERY large biotech firm out there would have to sit by and watch this monster potential die on the vine hoping to be the lucky one to buy it up dirt cheap.
Replacing diseased or damaged organ tissue isn't necessarily a cure, but could in many cases be a stop gap therapy that needs to be re-applied. And once Medicaid or Medicare and/or private insurance companies get on board, ONVO could sky rocket.
Just sayin...